| Osteoporosis
Evenity vs Forteo
Side-by-side clinical, coverage, and cost comparison for osteoporosis.Deep comparison between: Evenity vs Forteo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsForteo has a higher rate of injection site reactions vs Evenity based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Forteo but not Evenity, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Evenity
Forteo
At A Glance
SC injection
Every month
Sclerostin inhibitor
SC injection
Once daily
PTH analog
Indications
- Osteoporosis
- Osteoporosis
- Primary osteoporosis
- Osteoporosis steroid-induced
Dosing
Osteoporosis 210 mg subcutaneously once every month for 12 doses, administered as two separate 105 mg/1.17 mL injections in the abdomen, thigh, or upper arm by a healthcare provider; supplement calcium and vitamin D during treatment.
Osteoporosis, Primary osteoporosis, Osteoporosis steroid-induced 20 mcg subcutaneously once daily into the thigh or abdominal region; use for more than 2 years during a patient's lifetime only if the patient remains at or has returned to high risk for fracture.
Contraindications
- Hypocalcemia (correct pre-existing hypocalcemia prior to initiating therapy)
- History of systemic hypersensitivity to romosozumab-aqqg or any component of the product formulation, including angioedema, erythema multiforme, and urticaria
- Hypersensitivity to teriparatide or any of its excipients
Adverse Reactions
Most common (>=5%) Arthralgia, headache
Serious Major adverse cardiac events (myocardial infarction, stroke, cardiovascular death), hypersensitivity reactions (angioedema), hypocalcemia, osteonecrosis of the jaw, atypical subtrochanteric and diaphyseal femoral fractures
Most common (>10%) Arthralgia, pain, nausea
Postmarketing Anaphylactic reactions, angioedema, urticaria, drug hypersensitivity, osteosarcoma, hyperuricemia, acute dyspnea, chest pain, muscle spasms of the leg or back, injection site reactions, oro-facial edema
Pharmacology
Sclerostin inhibitor; humanized IgG2 monoclonal antibody that increases bone formation and, to a lesser extent, decreases bone resorption by inhibiting sclerostin, a regulatory factor in bone metabolism that suppresses osteoblastic activity.
Teriparatide is a recombinant human parathyroid hormone analog (PTH 1-34) that binds PTH cell-surface receptors and stimulates new bone formation by preferential stimulation of osteoblastic over osteoclastic activity on trabecular and cortical bone surfaces.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Evenity
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Forteo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Evenity
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Forteo
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (0/8)
Humana
Evenity
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Forteo
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Neurofibromatosis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EvenityView full Evenity profile
ForteoView full Forteo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.